Drug Type Small molecule drug |
Synonyms EPI 7386, EPI-7386 |
Target |
Action antagonists |
Mechanism AR antagonists(Androgen Receptor antagonists) |
Therapeutic Areas |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationFast Track (United States) |
Molecular FormulaC24H24Cl2N4O4S |
InChIKeyGVCZSODXLFBYSS-UHFFFAOYSA-N |
CAS Registry2416716-62-4 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Adenocarcinoma of prostate | Phase 2 | United States | 16 May 2024 | |
Adenocarcinoma of prostate | Phase 2 | United States | 16 May 2024 | |
Castration-sensitive prostate cancer | Phase 2 | United States | 16 May 2024 | |
Castration-sensitive prostate cancer | Phase 2 | United States | 16 May 2024 | |
Hormone-dependent prostate cancer | Phase 2 | United States | 16 May 2024 | |
Hormone-dependent prostate cancer | Phase 2 | United States | 16 May 2024 | |
Prostatic Cancer | Phase 2 | United States | 12 Apr 2023 | |
Metastatic castration-resistant prostate cancer | Phase 2 | United States | 21 Dec 2021 | |
Metastatic castration-resistant prostate cancer | Phase 2 | Australia | 21 Dec 2021 | |
Metastatic castration-resistant prostate cancer | Phase 2 | Canada | 21 Dec 2021 |
NCT05075577 (PRNewswire) Manual | Phase 2 | 120 | Enzalutamide 160mg QD | hbceffzvbv(ziomitqxxq) = wycozwibsm rhicjgxgsx (itwpmxejak ) Not Met View more | Negative | 31 Oct 2024 | |
hbceffzvbv(ziomitqxxq) = gztxivmfyp rhicjgxgsx (itwpmxejak ) Not Met View more | |||||||
Phase 1/2 | 18 | cauksqivgv(efaprcwgxo) = covpzkcwss mobxbtkwec (zxgtqkkzlr ) View more | Positive | 15 Sep 2024 | |||
Phase 1/2 | 16 | cpxhdoxmhz(dodyxygkim) = vixsdgiyxq antwatgywp (xtnvzwdvkl ) View more | Positive | 25 Jan 2024 | |||
Phase 1/2 | 11 | qispacbvek(uytktqtrpa) = consistent with second-generation antiandrogens (e.g., Grade 1 or 2 AEs of fatigue and hot flashes). jzrbayxyer (trojlyjcnd ) View more | Positive | 22 Oct 2023 | |||
Phase 1/2 | 7 | oqzaxnpxxi(ujoufhusdq) = wwqmnqxyew ehhandtsou (nurxbgwrdj ) View more | Positive | 21 Feb 2023 | |||
Phase 1 | 39 | eytazrtxgg(iuytyiijqy) = sdylshdnlm mrtoazdmgf (ecmramajzi ) | Positive | 21 Feb 2023 | |||
Phase 1 | 36 | rvbzwporjm(rwqewdhouk) = EPI-7386 was safe and well-tolerated at all dose levels and schedules tested with plasma target concentrations achieved and clinically important efficacy signals uplzefcokb (mdkmorking ) | Positive | 27 Jun 2022 |